구강용 박막 필름 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oral Thin Films Market size is expected to reach USD 16.24 Billion in 2034 from USD 5.58 Billion (2025) growing at a CAGR of 12.59% during 2026-2034.

The global oral thin films market is growing rapidly due to increasing demand for convenient and fast-acting drug delivery systems. These films dissolve quickly in the mouth without the need for water, making them highly suitable for pediatric, geriatric, and dysphagic patients. Rising preference for non-invasive and patient-friendly dosage forms is significantly contributing to market expansion, particularly in developed healthcare markets.

Growth drivers include advancements in drug formulation technologies, increasing adoption of self-administration therapies, and the expanding application of oral thin films in treating conditions such as pain, allergies, and neurological disorders. Pharmaceutical companies are investing in innovative film technologies to enhance bioavailability and ensure precise dosing. Additionally, the growing trend of personalized medicine is further supporting the adoption of these delivery systems.

Future prospects for the oral thin films market remain highly promising, with ongoing research focused on expanding their therapeutic applications. The integration of nanotechnology and improved polymer formulations is expected to enhance drug stability and effectiveness. Increasing healthcare awareness and accessibility in emerging economies will further boost market demand, making oral thin films a key component of modern drug delivery solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Sublingual Film
• Fast Dissolving Dental/Buccal Film

By Disease Indication

• Schizophrenia
• Migraine
• Opioid Dependence
• Nausea & Vomiting
• Other Disease Indication

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

COMPANIES PROFILED

• ZIM Laboratories Limited, NAL Pharma, Cure Pharmaceutical Holding Corp, IntelGenx Corp, Kyu Kyu Pharmaceutical Co Ltd, Sunovion Pharmaceuticals Inc, Seoul Pharma Co Ltd, Aquestive Therapeutics Inc, Shilpa Therapeutics Pvt Ltd, Mylan Inc, LIVKON Pharmaceuticals Pvt Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL THIN FILMS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Sublingual Film Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Fast Dissolving Dental/Buccal Film Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL THIN FILMS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Schizophrenia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Migraine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Opioid Dependence Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nausea & Vomiting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Disease Indication Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL THIN FILMS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL THIN FILMS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Disease Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Disease Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Disease Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Disease Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Disease Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL THIN FILMS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ZIM Laboratories Limited
  • 9.2.2 NAL Pharma
  • 9.2.3 Cure Pharmaceutical Holding Corp
  • 9.2.4 IntelGenx Corp
  • 9.2.5 Kyu Kyu Pharmaceutical Co. Ltd
  • 9.2.6 Sunovion Pharmaceuticals Inc
  • 9.2.7 Seoul Pharma Co. Ltd
  • 9.2.8 Aquestive Therapeutics Inc
  • 9.2.9 Shilpa Therapeutics Pvt. Ltd
  • 9.2.10 Mylan Inc
  • 9.2.11 LIVKON Pharmaceuticals Pvt. Ltd